Top Safest Stocks To Own For 2019

The anxiety, frustration and second-guessing builds during times like these, but you must remain vigilant and, more important, patient.

Since the market peaked at the end of January and subsequently slid into its first correction in two years, we’ve been patiently waiting to see whether this is “just” a correction or if it’s the start of the next bear market.

—Recommended Link— The Most Generous Income Producers You Can Get
We’re sitting on a collection of the safest, most generous monthly payers available. And while $11,200 in dividend checks is a welcome addition to anyone’s income, investors also love racking up capital gains as high as 446%.Start generating a 10%+ income stream for life today from these consistent companies.

But as the market consolidates before its next move, the anticipation can be almost too much for many investors. In times like these, mistakes are made and money is lost. Investing strategies and discipline get tossed out the window as traders base their next move on the daily swings of the market. Euphoria climbs when the S&P 500 ends the day in green, but it quickly fades the next day when the market opens lower.

Top Safest Stocks To Own For 2019: Viking Therapeutics, Inc.(VKTX)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of Viking Therapeutics (NASDAQ:VKTX) jumped nearly 14% today after Gilead Sciences (NASDAQ:GILD) announced that a closely watched drug candidate failed a phase 3 trial. The drug candidate, selonsertib, was being developed as a potential treatment for nonalcoholic steatohepatitis (NASH).

  • [By Money Morning News Team]

    While exciting, CODX and our other penny stocks to watch this week are unlikely to tack on any additional gains this week. But don’t worry. After looking at our 10 top penny stocks to watch, we’ll show you a stock with serious profit potential in its future…

    Penny Stock Current Share Price Last Week’s Gain
    Co-Diagnostics Inc. (Nasdaq: CODX)  $4.35 192.07%
    Viking Therapeutics Inc. (Nasdaq: VKTX)  $9.37 95.78%
    DHI Group Inc. (NYSE: DHX)  $3.10 67.57%
    Axovant Sciences Ltd. (Nasdaq: AXON)  $1.76 60.00%
    Netlist Inc. (Nasdaq: NLST)  $0.21 53.79%
    Link Motion Inc. (NYSE LKM)  $1.23 47.73%
    CorMedix Inc. (NYSE: CRMD)  $0.26 44.44%
    Vistagen Therapeutics Inc. (Nasdaq: VTGN)  $1.34 40.21%
    J. Jill Inc. (NYSE: JILL)  $8.30 36.55%
    Adomani Inc. (Nasdaq: ADOM)  $1.52 34.86%

    In order to make sure we protect ourselves from any substantial losses from investing in penny stocks, we follow five rules for penny stock investing. Take look at them on the right.As these stocks demonstrate, there are penny stocks that have tremendous growth potential that can easily dwarf your initial investment. However, most penny stocks lack the solid underlying financials necessary to generate a significant return.
    Fast Money: This powerful secret made one man a millionaire. Now he’s sharing it live on camera – find out how you could use it to become $2,918 richer in less than a minute. Click here…

  • [By Todd Campbell, Keith Speights, and Brian Feroldi]

    Investing in biotech stocks can be risky because clinical trial failures can lead to eye-popping drops in share prices. Nevertheless, the potential to benefit from revolutionary new medicines can make owning biotech stocks in a diversified portfolio smart. If you’re hunting for new biotech stocks to buy, these three Motley Fool investors think you should consider Ligand Pharmaceuticals (NASDAQ:LGND), Viking Therapeutics (NASDAQ:VKTX), and Amarin Corporation (NASDAQ:AMRN). Each of these companies has catalysts that could make now a good time to pick up shares.

  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares surged 144.96 percent to close at $265.61 on Thursday in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) shares rose 101.01 percent to close at $9.99 on Thursday after falling 4.42 percent on Wednesday.
    Akers Biosciences, Inc. (NASDAQ: AKER) jumped 45.58 percent to close at $0.474. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
    Kitov Pharma Ltd (NASDAQ: KTOV) gained 40.93 percent to close at $3.03 after the FDA approved Kitov's Consensi for the treatment of osteoarthritis pain and hypertension.
    China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 28.21 percent to close at $19.86.
    J.Jill, Inc. (NYSE: JILL) climbed 26.45 percent to close at $7.84 after the company posted upbeat quarterly earnings.
    Curis, Inc. (NASDAQ: CRIS) shares climbed 21.93 percent to close at $2.78 in reaction to an encouraging FDA update. The biotechnology company that focuses on therapies for the treatment of cancer said the FDA granted a Fast Track designation for fimepinostat (CUDC-907) in patients with relapsed or refractory.
    Boxlight Corporation (NASDAQ: BOXL) gained 21.23 percent to close at $7.48.
    Kirkland's, Inc. (NASDAQ: KIRK) rose 16.21 percent to close at $12.83 after reporting upbeat Q1 results.
    The Brink's Company (NYSE: BCO) jumped 16.2 percent to close at $79.25 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
    Applied Optoelectronics, Inc. (NASDAQ: AAOI) rose 15.14 percent to c

Top Safest Stocks To Own For 2019: FibroGen, Inc(FGEN)

Advisors’ Opinion:

  • [By Max Byerly]

    Hilltop Holdings Inc. lifted its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 2.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 55,140 shares of the biopharmaceutical company’s stock after buying an additional 1,530 shares during the period. FibroGen makes up approximately 0.7% of Hilltop Holdings Inc.’s holdings, making the stock its 22nd largest position. Hilltop Holdings Inc. owned approximately 0.07% of FibroGen worth $3,452,000 as of its most recent filing with the SEC.

  • [By Shane Hupp]

    FibroGen (NASDAQ:FGEN) was upgraded by analysts at ValuEngine from a buy rating to a strong-buy rating.

    Fulgent Genetics (NASDAQ:FLGT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $5.25 price target on the stock. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics, Inc. is headquartered in Temple City, California. “

  • [By Ethan Ryder]

    FibroGen (NASDAQ:FGEN) Director Jorma Routti sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, May 9th. The shares were sold at an average price of $47.10, for a total transaction of $282,600.00. Following the completion of the transaction, the director now directly owns 133,840 shares in the company, valued at approximately $6,303,864. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

  • [By Logan Wallace]

    FibroGen (NASDAQ:FGEN) was downgraded by equities researchers at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Top Safest Stocks To Own For 2019: Provident Financial Holdings, Inc.(PROV)

Advisors’ Opinion:

  • [By Ethan Ryder]

    E*TRADE Financial (NASDAQ: ETFC) and Provident Financial (NASDAQ:PROV) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

  • [By Logan Wallace]

    Charter Financial (NASDAQ: CHFN) and Provident Financial (NASDAQ:PROV) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

  • [By Max Byerly]

    News articles about Provident Financial (NASDAQ:PROV) have been trending somewhat negative this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Provident Financial earned a daily sentiment score of -0.02 on Accern’s scale. Accern also assigned news articles about the financial services provider an impact score of 45.9215692366566 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Top Safest Stocks To Own For 2019: El Pollo Loco Holdings, Inc.(LOCO)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ValuEngine upgraded shares of El Pollo LoCo (NASDAQ:LOCO) from a strong sell rating to a sell rating in a report issued on Tuesday.

    Several other research firms also recently weighed in on LOCO. BidaskClub upgraded El Pollo LoCo from a sell rating to a hold rating in a research report on Friday, June 22nd. SunTrust Banks set a $11.00 target price on El Pollo LoCo and gave the company a hold rating in a research report on Thursday, March 8th. Finally, Morgan Stanley restated an equal weight rating and issued a $11.00 target price (down previously from $12.00) on shares of El Pollo LoCo in a research report on Monday, March 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. El Pollo LoCo has a consensus rating of Hold and a consensus target price of $12.40.

  • [By Dan Caplinger]

    Wall Street finished the week on a low note on Friday, dealing another losing day to investors already hard-hit from declines in previous trading sessions. Today’s culprit was a poor labor report, which showed that the U.S. economy produced only 20,000 new nonfarm payroll jobs during the month of February. Many stocks suffered much more dramatic losses than the roughly 0.1% to 0.2% decline that major indexes saw, with earnings playing a key role for several of them. American Outdoor Brands (NASDAQ:AOBC), Eventbrite (NYSE:EB), and El Pollo Loco Holdings (NASDAQ:LOCO) were among the worst performers. Here’s why they did so poorly.

  • [By Motley Fool Transcribers]

    El Pollo Loco Holdings Inc  (NASDAQ:LOCO)Q4 2018 Earnings Conference CallMarch 07, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Nathan’s Famous (NASDAQ: NATH) and El Pollo LoCo (NASDAQ:LOCO) are both small-cap retail/wholesale companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Top Safest Stocks To Own For 2019: Cresud S.A.C.I.F. y A.(CRESY)

Advisors’ Opinion:

  • [By Max Byerly]

    Media headlines about Cresud S.A.C.I.F. y A. (NASDAQ:CRESY) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cresud S.A.C.I.F. y A. earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.7755181744414 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Stephan Byrd]

    News coverage about Cresud S.A.C.I.F. y A. (NASDAQ:CRESY) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cresud S.A.C.I.F. y A. earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6414670877177 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

  • [By Shane Hupp]

    Cresud S.A.C.I.F. y A. (NASDAQ:CRESY) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 294,367 shares, a decline of 44.8% from the April 30th total of 533,376 shares. Based on an average daily volume of 179,726 shares, the days-to-cover ratio is presently 1.6 days.

Leave a Reply

Your email address will not be published. Required fields are marked *